Long-term observation of antibody titers against SARS-CoV-2 following vaccination

[1]  M. Hernán,et al.  Fourth Dose of BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting , 2022, The New England journal of medicine.

[2]  Michael I. Mandel,et al.  Protection of BNT162b2 Vaccine Booster against Covid-19 in Israel , 2021, The New England journal of medicine.

[3]  P. Dormitzer,et al.  Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months , 2021, The New England journal of medicine.

[4]  B. Mizrahi,et al.  Correlation of SARS-CoV-2-breakthrough infections to time-from-vaccine , 2021, Nature Communications.

[5]  M. Lipsitch,et al.  Covid-19 Breakthrough Infections in Vaccinated Health Care Workers , 2021, The New England journal of medicine.

[6]  A. Griesmacher,et al.  Clinical validation of the Siemens quantitative SARS-CoV-2 spike IgG assay (sCOVG) reveals improved sensitivity and a good correlation with virus neutralization titers , 2021, Clinical chemistry and laboratory medicine.

[7]  Marcus D. Ruopp,et al.  Durability of SARS-CoV-2 IgG Antibody Among Residents in a Long-Term Care Community , 2021, Journal of the American Medical Directors Association.

[8]  P. Dormitzer,et al.  Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine , 2020, The New England journal of medicine.

[9]  M. Malim,et al.  Longitudinal observation and decline of neutralizing antibody responses in the three months following SARS-CoV-2 infection in humans , 2020, Nature Microbiology.

[10]  Mei San Tang,et al.  Association between SARS-CoV-2 neutralizing antibodies and commercial serological assays , 2020, bioRxiv.